Piramal Pharma Appoints Pratibha Mishra as Interim Company Secretary
Piramal Pharma Limited designated four new Senior Management Personnel. Ms. Tanya Sanish resigned as Company Secretary and Compliance Officer, effective Feb 20, 2026. Ms. Pratibha Mishra appointed as Interim Company Secretary and Compliance Officer from Feb 21, 2026.
Changes in key managerial personnel, especially the Company Secretary and Compliance Officer, can have a medium-term impact on corporate governance and regulatory compliance. The designation of new SMPs also signifies a strengthening of the management team.
The announcement details changes in senior management and the resignation and appointment of a Company Secretary. While these are routine corporate actions, they do not inherently indicate a positive or negative shift in the company's performance or outlook.
Piramal Pharma Limited (PPL) announced significant changes in its Senior Management Personnel (SMP) and Key Managerial Personnel (KMP) following a Board of Directors meeting held on January 28, 2026.
Four officials have been additionally designated as Senior Management Personnel: Ms. Rashida Najmi (Chief Quality Officer), Mr. Jatin Lal (President – Merger and Acquisitions), Mr. Sandeep Rathod (General Counsel), and Ms. Puneet Rajput (Chief Human Resource Officer). Brief profiles of these SMPs are provided, highlighting their extensive experience and roles within the company and its subsidiaries.
In a key development, Ms. Tanya Sanish has resigned from her position as Company Secretary and Compliance Officer, effective February 20, 2026, to pursue external career opportunities. Subsequently, the Board has approved the appointment of Ms. Pratibha Mishra as the Interim Company Secretary and Compliance Officer, a KMP of the Company, effective February 21, 2026. Ms. Mishra brings over a decade of experience in corporate secretarial and compliance functions for listed companies, including prior roles at CEAT Limited and CARE Ratings Limited, and was instrumental in the IPO of Nazara Technologies Limited.
What to do with a filing like this
Piramal Pharma Limited filed this with the NSE as a statutory disclosure, categorised under key management changes. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Piramal Pharma Limited. Read the original for the full detail.